If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


ACS News

CAS COVID-19 data set helps power PerkinElmer dashboard

by Linda Wang
July 31, 2020 | A version of this story appeared in Volume 98, Issue 30


PerkinElmer has launched two open ­access informatics tools that aim to accelerate the analysis of drug compound and clinical trial data. One of the dashboards includes the CAS COVID-19 ­Antiviral Candidate Compound Dataset of nearly 50,000 chemical substances with known or potential antiviral activity that could serve as leads against COVID-19.

Support nonprofit science journalism
C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support us:
Donate Join Subscribe

By collaborating with organizations like CAS on the COVID-19 dashboards, PerkinElmer put the power of analytics at the fingertips of scientists to help drive actionable insights earlier in the discovery process, according to Kevin Willoe, vice president and general manager of informatics at PerkinElmer. “These ­dashboards are tools to help them spend more time being scientists and less time being data managers, which is critical when working to combat the challenges faced by COVID-19 researchers.”

The second dashboard pulls data from sources like the US National Library of Medicine’s clinical trial registry, This dashboard helps scientists identify and analyze information on trials for COVID-19. More information on the data sets is available at


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.